REGENXBIO Inc. (RGNX)

REGENXBIO Inc. is trading at $11.98, up 8.22% on the session. The 50 day average sits at $10.06 and the 200 day at $n/a, which puts the stock in a mixed technical position. RSI is at 51.2, which reads as neutral, and MACD is bearish crossover. Volume is below average.

The nearest support is around $10.15 with resistance near $11.50, so that band frames the current range. Average daily movement is roughly $0.84, or about 7.0% of the share price, which is what any stop placement has to allow for. The overall health score of 48 out of 100 combines a trend score of 72, momentum of 30 and a risk score of 36.

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.